• Home
  • Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).

Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).

Author List
Ryan CJ, Dutta S, Kelly WK, Russell C, Small EJ, Morris MJ, Taplin ME, Halabi S, From The Alliance for Clinical Trials in Oncology Genitourinary Committee
Publication
Prostate cancer and prostatic diseases
Publication ID (Profile URL)
https://researcherprofiles.org/profile/57847551
Publication Year
2019
PubMed ID
31053766
Publication Title
Ryan CJ, Dutta S, Kelly WK, Russell C, Small EJ, Morris MJ, Taplin ME, Halabi S, From The Alliance for Clinical Trials in Oncology Genitourinary Committee. Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). Prostate Cancer Prostatic Dis. 2020 03; 23(1):66-73.